Medical Condition News

RSS

Experimental device for obstructive sleep apnea

Obstructive sleep apnea, a dangerous sleep disorder that affects millions of Americans may have found a cure. The disease commonly manifested as snoring but leading to tremendous sleep deprivation can be severely debilitating. Sleep deprivation may lead to car crashes, accidents, high blood pressure, heart attack, stroke, and diabetes.

29 Dec 2010

Controlling the amount of adipose tissue is key to combat obesity

Obesity is seen as the great pandemia of the XXI century. Recent data point to more than a billion adults in the world suffering from overweight, of which 300 million are clinically obese. What is more, the rates of child obesity show a worrying increase, with more than 155 million children and adolescents being overweight, of which 40 million are clearly obese.

29 Dec 2010

Merck confirms plans for developing vernakalant drug for atrial fibrillation

Cardiome Pharma Corp. today announced that it has been advised by its partner, Merck, that the current review of vernakalant is complete, and that Merck has informed Cardiome of its next steps in clinical development for vernakalant beginning in 2011.

29 Dec 2010

New innovative program to identify and treat combat veterans suffering from PTSD

An innovative program to identify and treat combat veterans suffering from Post Traumatic Stress Disorder - but who have not sought treatment - has been started by U.S.VETS, the nation's largest nonprofit devoted to providing housing and other services to homeless and at-risk veterans.

29 Dec 2010

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.

29 Dec 2010

Top weight-loss behaviors

Losing weight and saving money are the top New Year's resolutions expected to vex Americans this year, experts say.

29 Dec 2010

Researchers develop breath-analysis technology for rapid detection of biomarkers

Researchers have overcome a fundamental obstacle in developing breath-analysis technology to rapidly diagnose patients by detecting chemical compounds called "biomarkers" in a person's respiration in real time.

29 Dec 2010

Kennedy Krieger inagurates new clinic for AHO treatment and research

Kennedy Krieger Institute announced the opening of a new clinic for the treatment and research of Albright hereditary osteodystrophy (AHO), a rare genetic disorder affecting the bones, skin and hormone-producing tissues.

29 Dec 2010

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).

29 Dec 2010

New Year's Eve can be bad for your health

Research has shown that New Year's is the deadliest day of the year for pedestrians. Drinking and walking can be as dangerous as drinking and driving. Trauma surgeon Dr. Thomas Esposito has seen the tragic effects of drunk walking, among his patients and in his own family.

29 Dec 2010

Exposure to persistent organic pollutants alters cortisol level in blood

Karin E Zimmer's PhD research shows that persistent organic pollutants (POPs), such as PCB and mixtures of different POPs, affect the way the adrenal cortex functions and thereby the synthesis of the stress hormone cortisol.

28 Dec 2010

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

28 Dec 2010

HeartWare seeks FDA PMA approval for HeartWare Ventricular Assist System

HeartWare International, Inc. today announced that it has submitted a Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the HeartWare® Ventricular Assist System as a bridge to heart transplantation for patients with end-stage heart failure.

28 Dec 2010

BIOMICs oversees SGIker DNA Bank to know genetic heritage of Basque lineage

The BIOMICs Group, based at the Lucio Lascaray building in the álava/Araba campus of the University of the Basque Country, is specially known for overseeing the SGIker DNA Bank, not only undertaking this task, but also feeding data into the gene research bank and making good use of it for their own lines of research.

28 Dec 2010

Breast cancer survival techniques for dealing with challenges on the job and in life

As Lecheler celebrates the New Year, she is sharing her breast cancer survival techniques with business executives and others who are looking for a resolution they can keep - having a healthier and happier 2011. Lecheler offers up her integrated healing tips in her new book The Spirit to Heal.

28 Dec 2010

International reference standards for use of bone turnover markers in clinical studies recommended

An expert working group of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has released a new position paper which reviews the evidence of bone turnover markers (BTMs) in fracture risk prediction and monitoring of osteoporosis therapy. More importantly, it identifies research priorities and recommends that specific markers be used as reference analytes for BTMs in clinical and observational studies.

28 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Epilepsy not getting the public attention and research funding it deserves

Epilepsy, a common and serious neurologic disorder that affects millions of people, is not getting the public attention and funding for research it deserves, according to an editorial on a study published in the January 4, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

28 Dec 2010

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

Medical Condition News

Experimental device for obstructive sleep apnea

Controlling the amount of adipose tissue is key to combat obesity

Merck confirms plans for developing vernakalant drug for atrial fibrillation

New innovative program to identify and treat combat veterans suffering from PTSD

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Top weight-loss behaviors

Researchers develop breath-analysis technology for rapid detection of biomarkers

Kennedy Krieger inagurates new clinic for AHO treatment and research

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

New Year's Eve can be bad for your health

Exposure to persistent organic pollutants alters cortisol level in blood

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

HeartWare seeks FDA PMA approval for HeartWare Ventricular Assist System

BIOMICs oversees SGIker DNA Bank to know genetic heritage of Basque lineage

Breast cancer survival techniques for dealing with challenges on the job and in life

International reference standards for use of bone turnover markers in clinical studies recommended

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Epilepsy not getting the public attention and research funding it deserves

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News